Professional Experience:

2004 – Present            Principal Investigator/Sub-investigator

Affiliated Clinical Research, Inc.

501 S. Rancho, Suite C12, Las Vegas, NV

2012 – present             Michael S. Mall, MD

Medical Concierge Medical Practice

7455 W Washington Ave Suite #400

Las Vegas, NV 89128

2006—2012                Michael S. Mall, MD

Medical Concierge Practice

3201 S Maryland Parkway #220

Las Vegas, NV  89109

1995 – 2006                Primary Care

Office of Michael Scott Mall, MD

3201 S. Maryland Parkway, Suite 220

Las Vegas, Nevada

1990 – 1995                Staff Physician

Kenneth G. Fox, M.D. Ltd.

Las Vegas, Nevada

1987 – 1990                Resident Physician

Phoenix Baptist Hospital

Phoenix, Arizona

Professional Positions:

• Sunrise Hospital
• Vice Chief of Staff 2005-2007
• Board of Trustees 2003-2005
• Medical Executive Committee 1995-1997, 2001-2003
• Chief of Family Practice Department 1995-1997
• Chair of Medical Records Committee 1999-2007
• American Academy of Family Physicians Public Relations and Marketing Committee 1984 – 1987
• American Academy of Family Physicians Chairperson of the National Conference of Student Members 1984 – 1987

Licenses / Certifications / Awards:

• 1990 – 2011                Board Certified American Board Family Practice
• 1990 – Present            State of Nevada license # 6074
• Current                        Human Participant Protections Education for Research Teams, National Institute of Health (NIH) Course

 Memberships:

• Clark County Medical Society
• Las Vegas Metro Chamber of Commerce
• LAMBDA Chamber of Commerce
• Las Vegas Health & Fitness Chamber of Commerce (Charter Member)

Clinical Research Experience:

• A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of XXX for the Treatment of Vasomotor Symptoms of Menopause in Postmenopausal Women
• A Phase II, Double-Blind, Randomized, Dose-Cohort Escalation Study of Oral, Enteric-Coated XXX and Placebo in Patients with Chronic, Non-Malignant Pain and Opioid-Induced Constipation
• A Phase III, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active-Controlled Study to Evaluate the Safety and Efficacy of XXX Treatment in men with Secondary Hypoganadism
• A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXX (dosed as coadministered XXX  and XXX Tablets) Versus XXX in Patients with Mixed Hyperlipidemia
•  An Open Label, Dose Escalation, Multiple Center Study To Evaluate The Safety And Efficacy Of XXX™ Treatment In Men With Secondary Hypogonadism And Who Completed XXX
•  A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study of the Selective Progesterone Receptor Modulator XXX in Pre-Menopausal Women with Symptomatic Leiomyomata
• A Multicenter, Open-Label, Dose-Titration, Safety And Efficacy One Year Extension Study Of The Selective Progesterone Receptor Modulator XXX In Pre-Menopausal Women With Symptomatic Leiomyomata Who Have Previously Completed Study XXX
•  A Phase III, Flexible-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release XXX Compared to Placebo in Patients with Osteoarthritis Pain
•  A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study to Investigate the Safety and Efficacy of Orally Administered XXX  in Subjects with Symptomatic Osteoarthritis of the Knee
• Safety and Efficacy of XXXXXX versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia trachomatis Infection:  A Randomized, Double-blind, Double-dummy, Active-controlled Multicenter Study
• A Randomized, Parallel, Double-Blind, Placebo-Controlled Exploratory Study to Evaluate the Efficacy of XXXXX in Improving Glycemic Control in Men with Secondary Hypogonadism or Adult Onset Idiopathic Hypogonadotropic Hyprogonadism (AIHH) and Type 2 Diabetes mellitus with Sub-Optimum Treatment.
• A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men with Secondary Hypogonadism with Confirmed Morning Testosterone Levels <250 ng/dL that Wish to Preserve Their Reproductive Status and are Not Currently being Treated with Topical XXXXXXXX.
• A Randomized, Double-blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of XXXXXXXX/XXXXXXX Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy
•  A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Randomized Withdrawal Study To Evaluate The Analgesic Efficacy, Safety, And Tolerability Of XXXX In Opioid naive
• Subjects With Moderate To Severe Chronic Low Back Pain Requiring Around-The-Clock Opioid Analgesia For An Extended Period Of Time
•  A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Randomized Withdrawal Study To Evaluate The Analgesic Efficacy, Safety, And Tolerability Of XXXX In Opioid experienced Subjects With Moderate To Severe Chronic Low Back Pain Requiring Around-The-Clock Opioid Analgesia For An Extended Period Of Time
•  Qualitative Interviews with Patients Diagnosed with Endometriosis